{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:27:32Z","timestamp":1783592852513,"version":"3.55.0"},"reference-count":24,"publisher":"Bioscientifica","issue":"4","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gastrin receptor scintigraphy (GRS) is a new imaging method primarily developed for the detection of metastases of medullary thyroid carcinoma (MTC). As gastrin-binding CCK2 receptors are also expressed on a variety of other neuroendocrine tumours (NET), we compared GRS to somatostatin receptor scintigraphy (SRS) in patients with NET. SRS and GRS were performed within 21 days in a series of 60 consecutive patients with NET. GRS was directly compared with SRS. If lesions were visible on GRS but not detectable by SRS, other imaging modalities (MRI, CT) and follow-up were used for verification. Of the 60 evaluable patients, 51 had carcinoid tumours, 3 gastrinomas, 2 glucagonomas, 1 insulinoma and 3 paragangliomas. The overall tumour-detection rate was 73.7% for GRS and 82.1% for SRS. In the 11 patients with negative SRS, GRS was positive in 6 (54.5%). Based on the number of tumour sites detected and the degree of uptake, GRS performed better than SRS in 13 patients (21.7%), equivalent images were obtained in 18 cases (30.0%) and SRS performed better in 24 (40.0%) cases. In six of the SRS positive patients, 18 additional sites of tumour involvement could be detected. Overall, GRS detected additional tumour sites in 20% of the patients. Localisation of the primary tumours or their functional status had no influence on the outcome of imaging. GRS should be performed in selected patients as it may provide additional information in patients with NET with equivocal or absent somatostatin uptake.<\/jats:p>","DOI":"10.1677\/erc.1.01245","type":"journal-article","created":{"date-parts":[[2006,12,8]],"date-time":"2006-12-08T17:02:44Z","timestamp":1165597364000},"page":"1203-1211","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":56,"title":["Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours"],"prefix":"10.1530","volume":"13","author":[{"given":"Martin","family":"Gotthardt","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Postbus 9101, 6500 HB Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P","family":"Be\u0301he\u0301","sequence":"additional","affiliation":[{"name":"1Department of Nuclear Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Grass","sequence":"additional","affiliation":[{"name":"1Department of Nuclear Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Bauhofer","sequence":"additional","affiliation":[{"name":"2Institute of Theoretical Surgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Rinke","sequence":"additional","affiliation":[{"name":"3Departments of Gastroenterology and Endocrinology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike L","family":"Schipper","sequence":"additional","affiliation":[{"name":"1Department of Nuclear Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Kalinowski","sequence":"additional","affiliation":[{"name":"4Diagnostic Radiology, Philipps-University of Marburg, Baldingerstrasse, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Arnold","sequence":"additional","affiliation":[{"name":"4Diagnostic Radiology, Philipps-University of Marburg, Baldingerstrasse, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J G","family":"Oyen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Postbus 9101, 6500 HB Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M","family":"Behr","sequence":"additional","affiliation":[{"name":"1Department of Nuclear Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2026070906014992800_BAKKER-ETAL-1991","unstructured":"Bakker\n            WH\n          , Krenning EP, Reubi JC, Breeman WA, Setyono-Han B, de Jong M, Kooij PP, Bruns C, van Hagen PM, Marbach P et al.1991In vivo application of [111In-DTPA-D-PHE]-Octreotide for detection of somatostatin receptor-positive tumours in rats. Life Science491593\u20131601."},{"key":"2026070906014992800_BEHE-ETAL-2005","unstructured":"Behe\n            M\n          , Kluge G, Becker W, Gotthardt M & Behr TM 2005 Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. Journal of Nuclear Medicine461012\u20131015."},{"key":"2026070906014992800_BEHR-ETAL-1999A","unstructured":"Behr\n            TM\n          , Jenner M, Be\u0301he\u0301 M, Angerstein C, Gratz S, Raue F & Becker W 1999a Radiolabelled peptides for targeting of cholecystokinin-B\/gastrin receptor expressing tumours: from preclinical development to initial clinical results. Journal of Nuclear Medicine401029\u20131044."},{"key":"2026070906014992800_BEHR-ETAL-1999B","doi-asserted-by":"crossref","unstructured":"Behr\n            TM\n          , Behe M, Angerstein C, Gratz S, Mach R, Hagemann L, Jenner N, Stiehler M, Frank-Raue K, Raue F & Becker W 1999b Cholecystokinin-B\/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clinical Cancer Research53124s\u20133138s.","DOI":"10.1097\/00006231-200006000-00088"},{"key":"2026070906014992800_BLUM-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Blum\n            J\n          , Handmaker H, Lister-James J & Rinne N 2000 A multi-center trial with a somatostatin analog 99mTc-depreotide in the evaluation solitary pulmonary nodules. Chest1171232\u20131238.","DOI":"10.1378\/chest.117.5.1232"},{"key":"2026070906014992800_DE-VISSER-ETAL-2003","doi-asserted-by":"crossref","unstructured":"De Visser\n            M\n          , Janssen PJJM, Srinivasan A, Reubi JC, Waser B, Erion JL, Schmidt MA, Krenning EP & de Jong M 2003 Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging301134\u20131139.","DOI":"10.1007\/s00259-003-1189-y"},{"key":"2026070906014992800_DECRISTOFORO-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Decristoforo\n            C\n          , Mather SJ, Cholewinski W, Donnemiller E, Riccabona G & Moncayo R 2000 99mTc-EDDA\/HYNIC-TOC: a new 99mTc-labelled radiopharamceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. European Journal of Nuclear Medicine271318\u20131325.","DOI":"10.1007\/s002590000289"},{"key":"2026070906014992800_GOTTHARDT-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Gotthardt\n            M\n          , Boermann OC, Behr TM, Be\u0301he\u0301 MP & Oyen WJG 2004 Development and clinical application of peptide-based radiopharmaceuticals. Current Pharmaceutical Design102951\u20132963.","DOI":"10.2174\/1381612043383502"},{"key":"2026070906014992800_GOTTHARDT-ETAL-2006","doi-asserted-by":"crossref","unstructured":"Gotthardt\n            M\n          , Be\u0301he\u0301 M, Beuter D, Battmann A, Bauhofer A, Schurrat T, Schipper M, Pollum H, Oyen WJG, Behr TM 2006 Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging (in press).","DOI":"10.1007\/s00259-006-0157-8"},{"key":"2026070906014992800_GREWAL-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Grewal\n            RK\n          , Dadparvar S, Yu JQ, Babaria CJ, Cavanaugh T, Sherman M & Jacobstein J 2002 Efficacy of 99mTc-depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer Journal8400\u2013404.","DOI":"10.1097\/00130404-200209000-00011"},{"key":"2026070906014992800_HESSENIUS-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Hessenius\n            C\n          , Ba\u0308der M, Meinhold H, Bohmig M, Faiss S, Reubi JC & Wiedenmann B 2000 Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours. European Journal of Nuclear Medicine271684\u20131693.","DOI":"10.1007\/s002590000325"},{"key":"2026070906014992800_JANSSEN-ETAL-2002","unstructured":"Janssen\n            ML\n          , Oyen WJG, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, Rajopadhye M, Boonstra H, Corstens FH & Boerman OC 2002 Tumour targeting with radiolabelled \u03b1\u03bd\u03b23 integrin binding peptides in a nude mouse model. Cancer Research626146\u20136151."},{"key":"2026070906014992800_JUWEID-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Juweid\n            M\n          , Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic T, Hanley D, Markowitz A, Dunn R, Siegel J, Kamal T & Goldenberg DM 1996 Improved detection of medullary thyroid cancer with radiolabelled antibodies to carcinoembryonic antigen. Journal of Clinical Oncology141209\u20131217.","DOI":"10.1200\/JCO.1996.14.4.1209"},{"key":"2026070906014992800_KRENNING-ETAL-1993","doi-asserted-by":"crossref","unstructured":"Krenning\n            EP\n          , Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC et al.1993 Somatostatin receptor scintigraphy with (111In-DTPA-D-Phe1)- and (123I-Tyr3)-Octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine20716\u2013731.","DOI":"10.1007\/BF00181765"},{"key":"2026070906014992800_LAMBERTS-ETAL-1990","doi-asserted-by":"crossref","unstructured":"Lamberts\n            SW\n          , Bakker WH, Reubi JC & Krenning EP 1990 Somatostatin-receptor imaging in the localization of endocrine tumours. New England Journal of Medicine3231246\u20131249.","DOI":"10.1056\/NEJM199011013231805"},{"key":"2026070906014992800_LEBTAHI-ETAL-1997","unstructured":"Lebtahi\n            R\n          , Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M & le Guludec D 1997 Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumours. Journal of Nuclear Medicine38853\u2013858."},{"key":"2026070906014992800_MODLIN-AND-TANG-1997","doi-asserted-by":"crossref","unstructured":"Modlin\n            IM\n           & Tang LH 1997 Approaches to the diagnosis of gut neuroendocrine tumours: the last word today. Gastroenterology112583\u2013590.","DOI":"10.1053\/gast.1997.v112.pm9024313"},{"key":"2026070906014992800_REISINGER-ETAL-1998","unstructured":"Reisinger\n            I\n          , Bohuslavitzki KH, Brenner W, Braune S, Dittrich I, Geide A, Kettner B, Otto HJ, Schmidt S & Munz DL 1998 Somatostatin receptor scintigraphy in small cell lung cancer: results of a multicenter study. Journal of Nuclear Medicine39224\u2013227."},{"key":"2026070906014992800_REUBI-AND-WASER-2003","doi-asserted-by":"crossref","unstructured":"Reubi\n            JC\n           & Waser B 2003 Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor imaging. European Journal of Nuclear Medicine and Molecular Imaging30781\u2013793.","DOI":"10.1007\/s00259-003-1184-3"},{"key":"2026070906014992800_REUBI-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Reubi\n            JC\n          , Scha\u0308r JC, Waser B, Wenger S, Heppeler A, Schmitt JS & Macke HR 2000 Affinity profiles for human somatostatin receptor subtypes sst1\u2013sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. European Journal of Nuclear Medicine and Molecular Imaging27273\u2013282.","DOI":"10.1007\/s002590050034"},{"key":"2026070906014992800_RICKE-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Ricke\n            J\n          , Klose KJ, Mignon M, O\u0308berg K & Wiedenmann B 2001 Standardisation of imaing in neuroendocrine tumours: results of a European Delphi process. European Journal of Radiology378\u201317.","DOI":"10.1016\/S0720-048X(00)00187-X"},{"key":"2026070906014992800_TERMANINI-ETAL-1997","doi-asserted-by":"crossref","unstructured":"Termanini\n            B\n          , Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, Sutliff VE & Jensen RT 1997 Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology112335\u2013347.","DOI":"10.1053\/gast.1997.v112.pm9024287"},{"key":"2026070906014992800_VIRGOLINI-ETAL-1994","doi-asserted-by":"crossref","unstructured":"Virgolini\n            I\n          , Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W & Valent P 1994 Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumours. New England Journal of Medicine3311116\u20131121.","DOI":"10.1056\/NEJM199410273311703"},{"key":"2026070906014992800_VIRGOLINI-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Virgolini\n            I\n          , Britton K, Buscombe J, Moncayo R & Paganelli G 2002 Riva P 111In- and 90Y-DOTA-Lanreotide: results an implications of the MAURITIUS trial. Seminars in Nuclear Medicine32148\u2013155.","DOI":"10.1053\/snuc.2002.31565"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/13\/4\/0131203.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/13\/4\/1203\/150561\/0131203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/13\/4\/1203\/150561\/0131203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:02:01Z","timestamp":1783591321000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/13\/4\/1203\/26785\/Added-value-of-gastrin-receptor-scintigraphy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,1]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,12,1]]}},"URL":"https:\/\/doi.org\/10.1677\/erc.1.01245","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12,1]]}}}